OA
BIIB icon

Operose Advisors’s Biogen BIIB Stock Holding History

Operose Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$1.47K – 538
2026
Q1 		$1.47K Buy
+8
New +$1.47K ﹤0.01% 518
2024
Q4 		– Sell
-20
Closed -$3.88K – 451
2024
Q3 		$3.88K Hold
20
– – ﹤0.01% 550
2024
Q2 		$4.64K Hold
20
– – ﹤0.01% 501
2024
Q1 		$4.31K Hold
20
– – ﹤0.01% 554
2023
Q4 		$5.17K Hold
20
– – ﹤0.01% 525
2023
Q3 		$5.14K Buy
+20
New +$5.35K ﹤0.01% 659

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Operose Advisors's BIIB Position: Q2 2026 in Review

Operose Advisors sold out of Biogen (BIIB) in Q2 2026, closing a stake of 8 shares — an estimated $1.47K sold.

Operose Advisors first reported a position in BIIB in Q3 2023 and held it in 6 quarters. The position peaked at $5.17K in Q4 2023. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Operose Advisors reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
  • Operose Advisors sold 8 Biogen shares in Q2 2026, an estimated $1.47K.
  • Operose Advisors first reported a position in Biogen in Q3 2023 and held it in 6 quarters.
  • Operose Advisors's Biogen position peaked at $5.17K in Q4 2023.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.